Syntheses and characterization of non-bisphosphonate quinoline derivatives as new FPPS inhibitors

Background

Farnesyl pyrophosphate synthase (FPPS) is a key regulatory enzyme in the biosynthesis of cholesterol and in the post-translational modification of signaling proteins. It has been reported that non-bisphosphonate FPPS inhibitors targeting its allosteric binding pocket are potentially important for the development of promising anti-cancer drugs.

Methods

The following methods were used: organic syntheses of non-bisphosphonate quinoline derivatives, enzyme inhibition studies, fluorescence titration assays, synergistic effect studies of quinoline derivatives with zoledronate, ITC studies for the binding of FPPS with quinoline derivatives, NMR-based HAP binding assays, molecular modeling studies, fluorescence imaging assay and MTT assays.

Results

We report our syntheses of a series of quinoline derivatives as new FPPS inhibitors possibly targeting the allosteric site of the enzyme. Compound 6b showed potent inhibition to FPPS without significant hydroxyapatite binding affinity. The compound showed synergistic inhibitory effect with active-site inhibitor zoledronate. ITC experiment confirmed the good binding effect of compound 6b to FPPS, and further indicated the binding ratio of 1:1. Molecular modeling studies showed that 6b could possibly bind to the allosteric binding pocket of the enzyme. The fluorescence microscopy indicated that these compounds could get into cancer cells.

Conclusions

Our results showed that quinoline derivative 6b could become a new lead compound for further optimization for cancer treatment.

General significance

The traditional FPPS active-site inhibitors bisphosphonates show poor membrane permeability to tumor cells, due to their strong polarity. The development of new non-bisphosphonate FPPS inhibitors with good cell membrane permeability is potentially important.     

A more detailed picture of the interactions between virtual screening-derived hits and the DNA G-quadruplex: NMR, molecular modelling and ITC studies

The growing amount of literature about G-quadruplex DNA clearly demonstrates that such a structure is no longer viewed as just a biophysical strangeness but it is instead being considered as an important target for the treatment of various human disorders such as cancers or venous thrombosis. In this scenario, with the aim of finding brand new molecular scaffolds able to interact with the groove of the DNA quadruplex [d(TGGGGT)]₄, we recently performed a successful structure-based virtual screening (VS) campaign. As a result, six molecules were found to be somehow groove binders. Herein, we report the results of novel NMR titration experiments of these VS-derived ligands with modified quadruplexes, namely [d(TGG^BrGGT)]₄ and [d(TGGGG^BrT)]₄. The novel NMR spectroscopy experiments combined with molecular modelling studies, allow for a more detailed picture of the interaction between each binder and the quadruplex DNA. Noteworthy, isothermal titration calorimetry (ITC) measurements on the above-mentioned compounds revealed that 2, 4, and 6 besides their relatively small dimensions bind the DNA quadruplex [d(TGGGGT)]₄ with higher affinity than distamycin A, to the best of our knowledge, the most potent groove binder identified thus far.     

Allosteric modulators of human A2B adenosine receptor

Background

Among adenosine receptors (ARs) the A_2B subtype exhibits low affinity for the endogenous agonist compared with the A₁, A_2A, and A₃ subtypes and is therefore activated when concentrations of adenosine increase to a large extent following tissue damages (e.g. ischemia, inflammation). For this reason, A_2B AR represents an important pharmacological target.

Methods

We evaluated seven 1-benzyl-3-ketoindole derivatives (7–9) for their ability to act as positive or negative allosteric modulators of human A_2B AR through binding and functional assays using CHO cells expressing human A₁, A_2A, A_2B, and A₃ ARs.

Results

The investigated compounds behaved as specific positive or negative allosteric modulators of human A_2B AR depending on small differences in their structures. The positive allosteric modulators 7a,b and 8a increased agonist efficacy without any effect on agonist potency. The negative allosteric modulators 8b,c and 9a,b reduced agonist potency and efficacy.

Conclusions

A number of 1-benzyl-3-ketoindole derivatives were pharmacologically characterized as selective positive (7a,b) or negative (8c, 9a,b) allosteric modulators of human A_2B AR.

General significance

The 1-benzyl-3-ketoindole derivatives 7–9 acting as positive or negative allosteric modulators of human A_2B AR represent new pharmacological tools useful for the development of therapeutic agents to treat pathological conditions related to an altered functionality of A_2B AR.     

A monovalent agonist of TrkA tyrosine kinase receptors can be converted into a bivalent antagonist

Background

Receptor tyrosine kinases (RTK) act through dimerization. Previously it was thought that only bivalent ligands could be agonistic, whereas monovalent ligands should be antagonistic. This notion changed after the demonstration that monovalent ligands can be agonistic, including our report of a small molecule monovalent ligand “D3” that is a partial agonist of the NGF receptor TrkA. A bivalent “D3-linker-D3” was expected to increase agonism.

Methods

Dimeric analogs were synthesized and tested in binding, biochemical, and biological assays.

Results

One analog, 1-ss, binds TrkA with higher affinity than D3 and induces or stabilizes receptor dimers. However, 1-ss exhibited antagonistic activity, through two mechanisms. One mechanism is that 1-ss blocks NGF binding, unlike D3 which is non-competitive. Inhibition of NGF binding may be due to the linker of 1-ss filling the inter-receptor space that NGF traverses before docking. In a second mechanism, 1-ss acts as a pure antagonist, inhibiting NGF-independent TrkA activity in cells over-expressing receptors. Inhibition is likely due to 1-ss “freezing” the TrkA dimer in the inactive state.

Conclusions

Dimerization of an RTK can result in antagonism, through two independent mechanisms.

General significance

we report a small molecule monovalent agonist being converted to a bivalent antagonist.     

The first cyclomegastigmane rhododendroside A from Rhododendron brachycarpum alleviates HMGB1-induced sepsis

Background

Endangered plant species are a vital resource for exploring novel drug prototypes. A Korean endangered plant Rhododendron brachycarpum G. Don is a broad-leaved shrub native to northern Korea and central Japan. The high mobility group box 1 protein (HMGB1) could be a specific target for the discovery of novel antiseptic agents.

Methods

Gauge-invariant atomic orbital (GIAO) NMR chemical shift calculations were applied for investigation of stereochemical details with accuracy improved by application of DP4 analysis. In vitro antiseptic mechanisms were investigated utilizing immunofluorescence staining, ELISA and cell–cell adhesion assay. Cecal ligation and puncture (CLP) operation was employed to evaluate in vivo potential alleviating severe sepsis and septic shock.

Results

The first bicyclic megastigmane glucoside rhododendroside A (1) along with known megastigmane glucosides (2–5) were isolated from the leaves of R. brachycarpum. The structure of 1 was established by NMR analysis as well as comparison of the experimental chemical shifts with those of computed values employing DP4 application. In the CLP operation model that simulates severe sepsis, rhododendroside A (1) improved the survival rate up to 60%.

Conclusions

Our results exhibit that R. brachycarpum may produce a unique scaffold that is developed into a drug lead mitigating HMGB1-induced vascular pro-inflammatory stimuli and thus alleviating severe sepsis and related manifestations.

General significance

Discovery of new drug leads would warrant conservation efforts of endangered species.     

Synthesis,angiopreventive activity,and in vivo tumor inhibition of novel benzophenone–benzimidazole analogs

Aim

The development of anticancer drugs with specific targets is of prime importance in modern biology. This study investigates the angiopreventive and in vivo tumor inhibition activities of novel synthetic benzophenone–benzimidazole analogs.

Main methods

The multistep synthesis of novel benzophenone–benzimidazole analogs (8a–n) allowing substitution with methoxy, methyl and halogen groups at different positions on the identical chemical backbone and the variations in the number of substituents were synthesized and characterized. The newly synthesized compounds were further evaluated for cytotoxic and antiproliferative effects against Ehrlich ascites carcinoma (EAC) cells. The potent lead compounds were further assessed for antiangiogenic effects in a CAM model and a tumor-induced vasculature in vivo model. The effect of angioprevention on tumor growth was verified in a mouse model.

Key findings

The cytotoxicity studies revealed that compounds 8f and 8n are strongly cytotoxic. Analyzing the structure–activity relationship, we found that an increase in the number of methyl groups in addition to methoxy substitution at the para position of the benzoyl ring in compound 8n resulted in higher potency compared to 8f. Furthermore, neovessel formation in in vivo systems, such as the chorioallantoic membrane (CAM) and tumor-induced mice peritoneum models, was significantly suppressed and reflected the tumor inhibition observed in mice.

Significance

These results suggest the potential clinical application of compound 8n as an antiangiogenic drug for cancer therapy.     

Selective detection of Cathepsin E proteolytic activity

Background

Aspartic proteases Cathepsin (Cath) E and D are two different proteases, but they share many common characteristics, including molecular weight, catalytic mechanism, substrate preferences, proteolytic conditions and inhibition susceptibility. To define the biological roles of these proteases, it is necessary to elucidate their substrate specificity. In the present study, we report a new peptide–substrate that is only sensitive to Cath E but not Cath D.

Methods

Substrate e, Mca-Ala-Gly-Phe-Ser-Leu-Pro-Ala-Lys(Dnp)-DArg-CONH₂, designed in such a way that due to the close proximity of a Mca-donor and a Dnp-acceptor, near complete intramolecular quenching effect was achieved in its intact state. After the proteolytic cleavage of the hydrophobic motif of peptide substrate, both Mca and Dnp would be further apart, resulting in bright fluorescence.

Results

Substrate e showed a 265 fold difference in the net fluorescence signals between Cath E and D. This Cath E selectivity was established by having -Leu**Pro- residues at the scissile peptide bond. The confined cleavage site of substrate e was confirmed by LC-MS. The catalytic efficiency (K_cat/K_M) of Cath E for substrate e was 16.7 μM⁻¹ S⁻¹. No measurable catalytic efficiency was observed using Cath D and no detectable fluorescent changes when incubated with Cath S and Cath B.

Conclusions

This study demonstrated the promise of using the developed fluorogenic substrate e as a selective probe for Cath E proteolytic activity measurement.

General significance

This study forms the foundation of Cath E specific inhibitor development in further studies.     

Vanadium complexes with 2-pyridineformamide thiosemicarbazones: In vitro studies of insulin-like activity

Reaction of VOCl₂ with 2-pyridineformamide thiosemicarbazone (H2Am4DH) and its N(4)-methyl (H2Am4Me), N(4)-ethyl (H2Am4Et) and N(4)-phenyl (H2Am4Ph) derivatives in ethanol gave as products [VO(H2Am4DH)Cl₂] (1), [VO(H2Am4Me)Cl₂] · 1/2HCl (2), [VO(H2Am4Et)Cl₂] · HCl (3) and [VO(2Am4Ph)Cl] (4). Upon the dissolution of 1-4 in water, oxidation immediately occurs with the formation of [VO₂(2Am4DH)] (5), [VO₂(2Am4Me)] (6), [VO₂(2Am4Et)] (7) and [VO₂(2Am4Ph)] (8). The crystal and molecular structures of 5 and 6 were determined. Complexes 5-8 inhibited glycerol release in a similar way to that observed with insulin but showed a low enhancing effect on glucose uptake by rat adipocytes.     

Design and discovery of novel quinazolinedione-based redox modulators as therapies for pancreatic cancer

Background

Altered cellular bioenergetics and oxidative stress are emerging hallmarks of most cancers including pancreatic cancer. Elevated levels of intrinsic reactive oxygen species (ROS) in tumors make them more susceptible to exogenously induced oxidative stress. Excessive oxidative insults overwhelm their adaptive antioxidant capacity and trigger ROS-mediated cell death. Recently, we have discovered a novel class of quinazolinediones that exert their cytotoxic effects by modulating ROS-mediated signaling.

Methods

Cytotoxic potential was determined by colorimetric and colony formation assays. An XF24 Extracellular Flux Analyzer, and colorimetric and fluorescent techniques were used to assess the bioenergetics and oxidative stress effects, respectively. Mechanism was determined by Western blots.

Results

Compound 3a (6-[(2-acetylphenyl)amino]quinazoline-5,8-dione) was identified through a medium throughput screen of ~ 1000 highly diverse in-house compounds and chemotherapeutic agents for their ability to alter cellular bioenergetics. Further structural optimizations led to the discovery of a more potent analog, 3b (6-[(3-acetylphenyl)amino]quinazoline-5,8-dione) that displayed anti-proliferative activities in low micromolar range in both drug-sensitive and drug-resistant cancer cells. Treatment with 3b causes Akt activation resulting in increased cellular oxygen consumption and oxidative stress in pancreatic cancer cells. Moreover, oxidative stress induced by 3b promoted activation of stress kinases (p38/JNK) resulting in cancer cell death. Treatment with antioxidants was able to reduce cell death confirming ROS-mediated cytotoxicity.

Conclusion

In conclusion, our novel quinazolinediones are promising lead compounds that selectively induce ROS-mediated cell death in cancer cells and warrant further preclinical studies.

General significance

Since 3b (6-[(3-acetylphenyl)amino]quinazoline-5,8-dione) exerts Akt-dependent ROS-mediated cell death, it might provide potential therapeutic options for chemoresistant and Akt-overexpressing cancers.     

Calix[4]arene supported group 5 imido complexes

The reaction of imidoyl chlorides [V(NR)Cl₃] (R = Ph 1, Tol 2, tBu 3) and calix[4]arene methyl ether H₃Mecalix unexpectedly leads to the formation of the structurally characterized vanadium (IV) complex [VCl(Mecalix)] (4). Calix[4]arene methyl ether stabilized imido complexes of the type [V(NR)(Mecalix)] (R = Ph 7, Tol 8, tBu 9) were afforded from the reaction of [V(NR)Cl₃] (R = Ph 1, Tol 2, tBu 3) and the tris(lithium) or tris(sodium) salt of the calix[4]arene ether. The lithium salt [{Li₃(Mecalix)}₂] (5) is a dimer in the solid state, in which two monomeric trianions are bridged by lithium cations. Imido complexes [M(NR)(Mecalix)] (M = Nb: R = tBu, 12, R = Tol 13, R = Mes 14, R = Dipp 15; M = Ta: R = tBu 16, R = Tol 17) (Tol = 4-C₆H₄Me, Mes = 2,6-C₆H₃Me₂; Dipp = 2,6-C₆H₃iPr₂) have been prepared from structurally characterized [NbCl₂(Mecalix)] (10) and previously known [TaCl₂(Mecalix)] (11) via reaction with two equivalents of the appropriately metallated (Li, K) primary amine. The molecular structures of 13 and 15 confirm the mononuclear nature of these complexes.     

Interaction of Pt(II) and Pd(II) complexes of terpyridine with 1-methylazoles: A combined experimental and density functional study

The synthesis and characterization of several complexes of the composition [{M(terpy)}_n(L)](ClO₄)_m (M = Pt, Pd; L = 1-methylimidazole, 1-methyltetrazole, 1-methyltetrazolate; terpy = 2,2′:6′,2″-terpyridine; n = 1, 2; m = 1, 2, 3) is reported and their applicability in terms of a metal-mediated base pair investigated. Reaction of [M(terpy)(H₂O)]²⁺ with 1-methylimidazole leads to [M(terpy)(1-methylimidazole)](ClO₄)₂ (1: M = Pt; 2: M = Pd). The analogous reaction of [Pt(terpy)(H₂O)]²⁺ with 1-methyltetrazole leads to the organometallic compound [Pt(terpy)(1-methyltetrazolate)]ClO₄ (3) in which the aromatic tetrazole proton has been substituted by the platinum moiety. For both platinum(II) and palladium(II), doubly metalated complexes [{M(terpy)}₂(1-methyltetrazolate)](ClO₄)₃ (4: M = Pt; 5: M = Pd) can also be obtained depending on the reaction conditions. In the latter two compounds, the [M(terpy)]²⁺ moieties are coordinated via C5 and N4. X-ray crystal structures of 1, 2, and 3 are reported. In addition, DFT calculations have been carried out to determine the energy difference between fully planar [Pd(mterpy)(L)]²⁺ complexes Ip-IVp (mterpy = 4′-methyl-2,2′:6′,2″-terpyridine; L = 1-methylimidazole-N3 (I), 1-methyl-1,2,4-triazole-N4 (II), 1-methyltetrazole-N3 (III), or 3-methylpyridine-N1 (IV)) and the respective geometry-optimized structures Io-IVo. Whereas this energy difference is larger than 70 kJ mol⁻¹ for compounds I, II, and IV, it amounts to only 0.8 kJ mol⁻¹ for the tetrazole-containing complex III, which is stabilized by two intramolecular C-H?N hydrogen bonds. Of all complexes under investigation, only the terpyridine-metal ion-tetrazole system with N3-coordinated tetrazole appears to be suited for an application in terms of a metal-mediated base pair in a metal-modified oligonucleotide.     

Palladium(II) and platinum(II) complexes with polypyridylbenzene ligands

The ligands 1,3-bis(3-pyridyl)benzene (1), 1,3-bis(4-pyridyl)benzene (2) and 1,3,5-tris(4-pyridyl)benzene (3) have been prepared by Stille coupling of 3- or 4-trimethylstannylpyridine with the appropriate bromoarene. Ligands 1 and 2 react with [M(OTf)₂(dppp)] (M=Pd, Pt) to produce the dipalladium- or diplatinum-containing macrocycles [M₂(μ-1)₂(dppp)₂](OTf)₄ or [M₂(μ-2)₂(dppp)₂](OTf)₄. These have been characterized by NMR spectroscopy and mass spectrometry and, in the case of [Pd₂(μ-1)₂(dppp)₂](OTf)₄, by X-ray crystallography. The molecular structure of the [Pd₂(μ-1)₂(dppp)₂]⁴⁺ cation reveals a shallow arrangement of the aromatic rings, with the palladium atoms lying above and below. The tridentate ligand 3 reacts with [Pd(OTf)₂(dppp)] to produce a trimetallic species of the form [Pd₃(μ₃-3)₂(dppp)₃](OTf)₆.     

The triphenyltin(VI) complexes of NSAIDs and derivatives. Synthesis, crystal structure and antiproliferative activity. Potent anticancer agents

The novel triphenyltin(IV) esters of flufenamic acid (1), Hflu, [Ph₃Sn(flu)] (2), and of [2-(2,3-dichlorophenylamino)benzoic acid] (3), Hdcpa, [Ph₃Sn(dcpa)] (4) have been structurally characterized by means of vibrational and ¹H, ¹³C NMR spectroscopic studies. The crystal and molecular structures of [SnPh₃(dcpa)(DMSO)] 4a are described. The molecular structure of 4a reveals that the Sn atom has a distorted trigonal bipyramidal coordination geometry with equatorial phenyl groups and the carboxylate and dimethylsulfoxide oxygen atoms occupying axial positions. The crystal structure of 4a is self-assembled by C-H---π and π-π stacking interactions. The in vitro cytotoxic activity of 1-4 and of the related non-steroidal anti-inflammatory drugs, NSAIDs, [2-(2,6-dimethylphenylamino)benzoic acid], Hdmpa (5), [Ph₃Sn(dmpa)] (6), [2-(2,3-dimethylphenylamino)benzoic acid], mefenamic acid, Hmef (7) and [Ph₃Sn(mef)] (8) has been evaluated against the cancer cell lines MCF-7, T-24, A-549 and L-929. The ligands exhibited very poor cytotoxic activity against the four cancer cell lines. Complex 6 exhibits the highest activity and selectivity against A-549 and MCF-7 cancer cell lines and complex 8 the highest activity and selectivity against T-24 cancer cell line. The cytotoxic results indicate that coupling of Hdmpa and Hmef with R₃Sn(IV) metal center results in complexes with important biological properties and remarkable cytotoxic activity, since they display IC₅₀ values in a μΜ range better to that of the antitumor drug cis-platin. Complexes 6 and 8 are considered as excellent antitumor compounds and the results of this study represent the discovery of triphenyltin(IV)esters as a potential novel class of anticancer agents.     

Synthesis and some reactivity of amidinato(pyridine) complexes of molybdenum and tungsten formulated as [M(η-allyl)(amidinato)(CO)2(NC5H5)]

Bis(pyridine) complexes of molybdenum and tungsten, [M(η³-allyl)Cl(CO)₂(NC₅H₅)₂] (M=Mo; 3-Mo, M=W; 3-W), reacted with an equimolar amount of lithiated amidinate, Li[(PhN)₂CR] (R=H; 4a-Li, R = CH₃; 4b-Li), to yield corresponding amidinato(pyridine) complexes, [M(η³-allyl){(PhN)₂CR}(CO)₂(NC₅H₅)] (M=Mo, R=H; 5a-Mo, M=Mo, R=CH₃; 5b-Mo, M=W, R=H; 5a-W), as a yellow solid. The dissociation of pyridine ligand from the central metal in complexes 5a was observed in a polar solvent such as acetonitrile. In these cases, although the formation of amidinato(acetonitrile) complexes, [M(η³-allyl){(PhN)₂CH}(CO)₂(NCMe)] (M=Mo; 6a-Mo, M=W; 6a-W), was suggested spectroscopically, isolation of complexes 6a was not successful but the re-formation of pyridine complexes 5a was observed. In the reactions of complexes 5a with PEt₃ and with P(OMe)₃, the substitution reactions easily took place to give [M(η³-allyl){(PhN)₂CH}(CO)₂(PEt₃)] (M=Mo; 7a-Mo, M=W; 7a-W) and [M(η³-allyl){(PhN)₂CH}(CO)₂{P(OMe)₃}] (M=Mo; 8a-Mo, M=W; 8a-W), respectively. These complexes were characterized spectroscopically as well as, in some cases, by X-ray analyses.     

Platinum(II) and palladium(II) saccharinato complexes with 2,2′:6′,2″-terpyridine: Synthesis, characterization, crystal structures, photoluminescence and thermal studies

[Pd(sac)(terpy)](sac)·4H₂O (1), [Pt(sac)(terpy)](sac)·5H₂O (2), [PdCl(terpy)](sac)·2H₂O (3) and [PtCl(terpy)](sac)·2H₂O (4) (sac = saccharinate, and terpy = 2,2′:6′,2″-terpyridine) have been synthesized and characterized by elemental analysis, FT-IR, ¹H NMR and ¹³C NMR. In 1 and 2, a tridentate terpy ligand together with an N-coordinated sac ligand form the square-planar geometry around the palladium(II) or platinum(II) ions, while one sac anion remains outside the coordination sphere as a counter-ion. X-ray single crystal studies show that the [M(sac)(terpy)]⁺ ions in 1 and 2 reside in the centers of a hydrogen bonded honeycomb network formed by the uncoordinated sac ions and the lattice water molecules. Complexes 3 and 4 are isostructural and consist of a [M(Cl)(terpy)]⁺ cation, a sac anion and two lattice water molecules. The [M(Cl)(terpy)]⁺ ions interact with each other via M-M and π-π stacking interactions and these π interacted units are assembled to a 2D network by water bridges involving the sac ions and lattice water molecules. Convenient synthetic paths for 1-4 are also presented, and spectral, luminescence and thermal properties were discussed.     

Synthesis and electrochemical studies of octahedral nickel β-diketonate complexes

The reaction of [Ni(tmhd)₂] and [Ni(dbm)₂] with N-donor chelating ligands in dichloromethane and acetone, respectively, yields the complexes [Ni(tmhd)₂(L-L)] (L-L = 2,2′-bpy 1, phen 2 and dmae 3) and [Ni(dbm)₂(L-L)] (L-L = 2,2′-bpy 4, phen 5, dmae 6). UV-Vis spectroscopy shows very strong bands in the UV region consistent with ligand centred π → π^∗ transitions. The electrochemical studies of 1-6 reveal oxidation to Ni(III). The [Ni(tmhd)₂(L-L)] 1-3 are more easily oxidized by ca. 300 mV and are quasi-reversible whereas for the [Ni(dbm)₂(L-L)] series only complex 6 shows significant reversibility. X-ray crystallographic studies have been conducted in the case of [Ni(dbm)₂(phen)] 5 and [Ni(dbm)₂(dmae)] 6. The structures both show that the nickel metal centre is octahedral with an O₄N₂ coordination environment. In the structures the β-diketonate ligands exhibit a cis-arrangement, with the metal displaced out of the planar chelate ring.     

Study of the cytotoxic activity of di and triphenyltin(IV) carboxylate complexes

The reaction of 3-methoxyphenylacetic acid (3-MPAH), 4-methoxyphenylacetic acid (4-MPAH), 2,5-dimethyl-3-furoic acid (DMFUH) or 1,4-benzodioxane-6-carboxylic acid (BZDOH) with triphenyltin(IV) chloride (1:1) or diphenyltin(IV) dichloride (2:1) in the presence of triethylamine yielded the compounds [SnPh₃(3-MPA)] (1), [SnPh₃(4-MPA)] (2), [SnPh₃(DMFU)] (3), [SnPh₃(BZDO)] (4), [SnPh₂(3-MPA)₂] (5), [SnPh₂(4-MPA)₂] (6), [SnPh₂(DMFU)₂] (7) and [SnPh₂(BZDO)₂] (8), respectively. The tetranuclear complex [{Me₂(DMFU)SnOSn(DMFU)Me₂}₂] (9) was prepared by the reaction of dimethyltin(IV) oxide and 2,5-dimethyl-3-furoic acid (DMFUH). The molecular structures of 3, 4 and 9, were determined by X-ray diffraction studies. The cytotoxic activity of the carboxylic acids (3-MPAH, 4-MPAH, BZDOH and DMFUH) and di (5-8) and triphenyltin(IV) complexes (2-4) was tested against tumor cell lines human adenocarcinoma HeLa, human myelogenous leukemia K562, human malignant melanoma Fem-x and normal immunocompetent cells, peripheral blood mononuclear cells PBMC. Triphenyltin(IV) complexes show higher activities than the diphenyltin(IV) derivatives. The most active compound is [SnPh₃(DMFU)] (3) with IC₅₀ value of 0.15 ± 0.01, 0.051 ± 0.004, 0.074 ± 0.004, 0.20 ± 0.01, 0.15 ± 0.02 on HeLa, K562, Fem-x, rested and stimulated PBMC, respectively, while the most selective are [SnPh₂(3-MPA)₂] (5), [SnPh₂(DMFU)₂] (7) and [SnPh₂(BZDO)₂] (8). Compounds 3, 5, 7 and 8 present higher activities than cisplatin in all the tested cells and relative high selectivity especially on K562 cells.     

Four metal-organic networks based on benzene-1,4-dioxyacetic acid and dipyrido[3,2-a:2′,3′-c]phenazine ligand

Four structurally diverse complexes, [Cd(dppz)(bdoa)]_n (1), [Zn(dppz)(bdoa)(H₂O)]_n (2), [Fe(dppz)₂(bdoa)]_n·2nH₂O (3), and [Co₂(dppz)₂(bdoa)₂(H₂O)]_n·3nH₂O (4), where H₂bdoa = benzene-1,4-dioxyacetic acid and dppz = dipyrido[3,2-a:2′,3′-c]phenazine, have been hydrothermally synthesized. Compounds 1-4 feature chain structures. There exist π-π interactions in the structures of 1, 2 and 4. Two neighboring chains of 1 are linked through the π-π interactions into a double chain supramolecular structure. The chains of 2 and 4 are further extended by the π-π interactions to form 3D and 2D supramolecular structures, respectively. The structural differences among such complexes show that the transition metals have important influences on their structures. The photoluminescent property of complex 2 and the magnetic property of complex 4 have also been investigated.